Q3 FY2025 Earnings
Financial report interval: 2025.06.30 - 2025.09.30
Overview: Apimeds Pharmaceuticals US(APUS) the EBIT is -1.844 M (-514.8%);the EPS is -0.142 (-236.7%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.00B514.75%
----
----
EPS
-0.1416236.67%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf